Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...

Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends for Bio-Rad Laboratories, Inc. With me on the call today are Norman D.

Assessing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has attracted attention after a mixed stretch of returns, with the stock roughly flat over the past year but showing ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju ...

With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...

While analyzing Bio-Rad Laboratories’ (BIO) most recent 10-K, my firm’s analysts noticed that its non-operating income not only overstates GAAP net income but could negatively impact the firm’s ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Bio-Rad develops products and solutions for the life science research and clinical diagnostic markets and has niche market leadership in diagnostic quality controls, antigens, and digital polymerase ...